Request Demo
Last update 29 May 2025
Ofloxacin
Last update 29 May 2025
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms floxacin and Sodium Chloride, Of1oxacin, Ofloxacin (JP17/USP/INN) + [56] |
Action inhibitors |
Mechanism Bacterial DNA gyrase inhibitors(Bacterial DNA gyrase inhibitors), Bacterial top IV inhibitors(Bacterial topoisomerase IV inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date Japan (16 Apr 1985), |
RegulationOrphan Drug (United States), Orphan Drug (Japan) |
Login to view timeline
Structure/Sequence
Molecular FormulaC18H20FN3O4 |
InChIKeyGSDSWSVVBLHKDQ-UHFFFAOYSA-N |
CAS Registry82419-36-1 |
Related
40
Clinical Trials associated with OfloxacinCTRI/2025/04/084740
To assess the effect of topical ofloxacin combination of topical ofloxacin and topical povidine iodine on conjuntival flora in preoperative cataract surgery patients - NIL
CTRI/2024/09/074346
Evaluation of a novel bilayer film loaded with ornidazole and ofloxacin for the treatment of patients with moderate periodontitis – A randomized controlled trial - NIL
NCT05302531
Absorption of Antibiotics With High Oral Bioavailability in Short-bowel Syndrome : a Monocentric Pilot Study
100 Clinical Results associated with Ofloxacin
Login to view more data
100 Translational Medicine associated with Ofloxacin
Login to view more data
100 Patents (Medical) associated with Ofloxacin
Login to view more data
21,867
Literatures (Medical) associated with Ofloxacin31 Dec 2025Gut Microbes Reports
Characterization of an Indigenous Lytic Phage Targeting Multidrug-Resistant
Salmonella enterica
Author: Emencheta, Stephen ; Akpa, Paul ; Eze, Emmanuel ; Onuigbo, Ebele ; Obeta, Chinonye ; Attama, Anthony
Multidrug-resistant pathogens have prompted the use of lytic bacteriophages.An indigenous novel lytic bacteriophage against Salmonella enterica strains from environmental wastewater was isolated and characterized using phage survivability study, adsorption curve, one-step curve, optimal multiplicity of infection, and phage-killing assay.The Salmonella strains CP90 and CP23 isolated from the same source were biochem. and molecularly characterized.The Salmonella strains CP90 and CP23 had 96.24% and 97.18% pairwise identity resp. with S. enterica.Both were resistant to B-lactam Aminoglycosides, Penicillin, and Phenicol class of antibiotics.The phage performed better in an alk. medium and below 50°C.About 80% of the phage had an adsorption rate of 12 min and a latent period of 20 min.About 55 PFU/cell of the phage was released during a single replication cycle, inhibiting bacteria growth for up to 5 h.The characterization of this indigenous phage suggests its therapeutic potential against multidrug-resistant Salmonella species.
01 Oct 2025Anti-Cancer Agents in Medicinal Chemistry
From Bench to Bioactivity: Pyranopyrazole Synthesis, Anticancer, Antimicrobial
Efficacy, DFT, Molecular Docking, and Molecular Dynamic Insights
Article
Author: Alamri, Abdullah A. ; Ismail, Khatib Sayeed ; Borik, Rita M.A. ; Mostafa, Mohamed S. ; Mohamed, Hany M. ; Al-Dies, Al-Anood M. ; Elhenawy, Ahmed A. ; Abdelwahab, Ashraf H. F.
Background::
Heterocyclic compounds are prevalent in nature and essential to life. The synthesis and
application of medium-sized ring heterocyclic compounds have gained prominence. Pyranopyrazole is one such
compound that has a significant impact on biological and medicinal chemistry. It has attracted interest in agrochemical
research due to its fungicidal, bactericidal, and herbicidal properties. Additionally, it exhibits various
biological activities, including anti-inflammatory, analgesic, antidiabetic, antimicrobial, anticancer, and antimalarial
effects. Furthermore, it has been explored for its potential in treating SARS-CoV-2.
Objective::
The study synthesized novel pyranopyrazole compounds and evaluated their anticancer efficacy
against certain tumor cell lines (MCF-7, HeLa, and PC-3) and antimicrobial activities as deduced through molecular
docking studies.
Methods::
A one-pot, four-component reaction involving ethyl acetoacetate (1), hydrazine hydrate (2), malononitrile
or ethyl cyanoacetate (3a, b), and aromatic aldehydes (4a-c) in an ethanolic/piperidine solution was conducted,
yielding pyranopyrazoles (5a-f) in moderate to good yields.
Results::
This study involved the synthesis of novel pyranopyrazole derivatives 5a-f and the evaluation of their
anticancer and antimicrobial activities. These findings indicate that compound 5f is extremely active. It is more
potent than 5-fluorourcail and ofloxacin, and it may also have new modes of action that are worth more research,
while compound 4d has the highest antimicrobial activity. Molecular docking studies help us learn more about
how these chemicals interact with biological targets like the TGF-βI receptor and the choline-binding domain,
both of which play a key role in the growth of cancer.
Conclusion::
A series of novel pyranopyrazole derivatives 5a-f were synthesized and analyzed using spectral data.
Compound 5f stands out as a lead molecule for more study and improvement due to its low IC50 value and high
binding affinity. Based on how stable it is in molecular dynamics (MD) simulations and how its anticancer properties
are linked to its binding affinities, it may be a strong TGF-βI receptor inhibitor.
01 Sep 2025Water Research X
Integrated social development on analyzing the distribution, risk and source apportionment of antibiotics pollution in mountainous rivers
Author: Shao, Ying ; Shen, Dongjun ; Ao, Liang ; Chen, Zhongli ; Yang, Minjie ; Fan, Wei
Antibiotics, as the widespread drugs stimulate the evolution of antibiotic resistance, threatening human and ecosystem health worldwide.Studies rarely conducted in rivers among the regional scale with diverse economic development, which limits the management efficient of antibiotic control.We investigated the concentration, distribution, risk and source apportionment of 54 antibiotics in 9 mountainous rivers, where the economic social development divers among their watersheds in Chongqing, China.The results showed that the concentrations of antibiotics detected in surface water, effluent of wastewater treatment plants, hospital, livestock and aquaculture sewage were 0.13-290 ng/L, 2.17-590 ng/L, 6.58-2.16 x 105 ng/L, 4.5-7.4 x 105 ng/L and 4.41-7.49 x 103 ng/L, resp.The order of total antibiotic concentrations along the investigated rivers was Laixi River > Changshou Lake > Longxi River > Fujiang River > Jialing River > Qiongjiang River > Yangtze River > Wujiang River > Qijiang River.The risk quotient indicates that ofloxacin and lincomycin exhibited high risk.Through Mantel test and correlation anal. screened antibiotics associated with anthropogenic factors.Municipal wastewater had a pos. impact on QNs.The pos. matrix factorization model was used to identify the main sources of antibiotics in surface water with special focus on the Longxi River, revealing the livestock and aquaculture were main contributions, resp.The ToxPi method was employed to prioritize antibiotics in surface water, and seven compounds were recommended as priority chems. of concern in the future.This work provides a valuable regional scale dataset of antibiotics in the mountainous rivers, which promises valuable insights for controlling antibiotic contamination.
7
News (Medical) associated with Ofloxacin29 Nov 2024
100 Deals associated with Ofloxacin
Login to view more data
R&D Status
Approved
10 top approved records. to view more data
Login
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Infectious Diseases | United States | 16 Dec 1997 | |
| Corneal Ulcer | United States | 28 Dec 1990 | |
| Trachoma | Japan | 01 Jun 1989 | |
| Blepharitis | Japan | 30 Jun 1987 | |
| Conjunctivitis | Japan | 30 Jun 1987 | |
| Dacryocystitis | Japan | 30 Jun 1987 | |
| Hordeolum | Japan | 30 Jun 1987 | |
| Keratitis | Japan | 30 Jun 1987 | |
| Bacterial Infections | Japan | 16 Apr 1985 | |
| Otitis Externa | Japan | 16 Apr 1985 | |
| Otitis Media | Japan | 16 Apr 1985 |
Developing
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Acute otitis media | Phase 3 | - | 01 Nov 2002 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Not Applicable | 114 | Small incision lenticule extraction+Proxymetacaine 0.5%+Oxybuprocaine 0.4%+Tobramycin and dexamethasone+Ofloxacin | tnnxyvgpbz(duaqggyqap) = xiercgajtq erjmjixrcb (yjmlpelkrh, 0.48) View more | - | 23 Apr 2024 | ||
Phase 4 | 38 | (DMEK) | lfwklktkum(mhuntrutex) = mbdqbwvlgq yrrhpyupmf (dvxpjfcszn, 0.11) View more | - | 02 Jul 2019 | ||
(DSAEK) | tjqsvplfxi(bzxpfvulty) = okcwbcaqmq hbjuvmjeve (myvuwlmako, 0.136) View more | ||||||
Not Applicable | - | Quinolones (Anaphylaxis patients) | hpuzgslkjx(wwxmilggns) = emlmmogqgb xlkvpfingc (qeufuiyiap ) | Positive | 01 Feb 2010 | ||
Quinolones (Urticaria patients) | hpuzgslkjx(wwxmilggns) = zlcgbjqqjv xlkvpfingc (qeufuiyiap ) | ||||||
Not Applicable | 8 | (Patients with multi-drug resistant tuberculosis) | mohhjwfkvk(xnebbhehpg) = pwcvynpfxi xwanlgevje (tdpoowiqdj ) View more | - | 01 Jan 2009 | ||
(Patients co-infected with multi-drug resistant tuberculosis and HIV/AIDS) | mohhjwfkvk(xnebbhehpg) = bvflhomppv xwanlgevje (tdpoowiqdj ) View more | ||||||
Not Applicable | - | hrtifkuhqw(zvsblyrwux) = ndypndgmxr faaslbreub (ppijhwfeeh, 48 - 216) | - | 23 Jun 2004 | |||
hrtifkuhqw(zvsblyrwux) = tlhkcabvdz faaslbreub (ppijhwfeeh, 48 - 262) |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free